Published online Nov 15, 2015. doi: 10.4251/wjgo.v7.i11.303
Peer-review started: May 15, 2015
First decision: July 1, 2015
Revised: July 15, 2015
Accepted: August 13, 2015
Article in press: August 14, 2015
Published online: November 15, 2015
Core tip: Gastric cancer, despite its decrease in West Countries, remains one of the most common malignancies worldwide. The prognosis in the advanced setting is often poor even with a multidisciplinary approach, which aims to increase the patients’ survival. The molecular classification of four subtypes of gastric adenocarcinomas (The Cancer Genome Atlas project) allowed a better stratification of patients in clinical trials for targeted therapies. Biologic agents, modulating the immune checkpoints, seem to be the best promising therapeutic approach, opening new perspective for advanced gastric cancer treatment.